Hyderabad: November 02nd, 2026: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended September 30, 2026.
Financial Summary (All numbers in INR Mn)
|
QUARTERLY CONSOLIDATED FINANCIALS |
Q2FY27 |
Q1FY27 |
Growth (QoQ) |
Q2FY26 |
Growth (YoY) |
|
Revenue from Operations |
15,600 | 14,768 | 6% | 12,970 | 20% |
|
EBITDA |
3,376 | 3,389 | 0% | 2,782 | 21% |
|
EBITDA % |
22% | 23% |
|
21% |
|
|
PBT |
2,434 | 2,404 | 1% | 1,759 | 38% |
|
PAT |
1,818 | 1,800 | 1% | 1,306 | 39% |
|
PAT % |
12% | 12% |
|
10% |
|
Financial and Business Summary for Q2FY27
§ Revenue from Operations of Q2FY27 stood at INR 15,600 Mn, a growth of 20% YoY, Revenue share from the North America is 72% in Q2FY27 as compared to 76% in Q2FY26 and from the Europe is 16% in Q2FY27 as compared to 12% in Q2FY26.
§ Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides CDMO contribute 73%, 13%, 10% and 3% of revenue from operations respectively for Q2FY27.
§ ROCE is at 17.6% in Q2FY27 in par with FY26.
§ Closed the quarter with a net cash position of ₹8,280 million, compared with net debt of ₹1,012 million in Q1 FY27.
Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “Our Quarterly revenue has crossed ₹1500 Cr in Q2 FY27 with EBITDA of ₹338 Cr, despite higher input and logistics costs from tensions in West Asia. Cost pressures will persist and we are working with customers to manage them with a lag. We filed two potential first-to-file ANDAs in H1, which makes it a total of three potential first to file ANDAs and continue to shift towards complex generics and peptide CDMO. With the balance warrant proceeds received, we hold net cash of ₹828 Cr to invest in R&D, manufacturing and quality”.
